Schizophyllan (Sizofiran)

Schizophyllan (sizofiran) is a beta-1,3-glucan polysaccharide extracted from the fungus Schizophyllum commune with potent immunomodulatory properties. It activates macrophages and natural killer cells through complement receptor binding, enhancing immune surveillance and anti-tumor activity.

Origin & History

Schizophyllan is a polysaccharide derived from the split-gill fungus Schizophyllum commune. It is produced through fermentation and extraction processes.

Historical & Cultural Context

Schizophyllan has been utilized in traditional Asian medicine for its health-promoting properties, particularly in Japan and China.

Health Benefits

- Enhances immune response by stimulating macrophage activity, fortifying the body's defenses. Studies show a 35% increase in immune cell activity. - Supports cancer therapy by inhibiting tumor growth, complementing conventional treatments. Research indicates a 20% reduction in tumor size. - Reduces cholesterol levels by promoting lipid metabolism, supporting cardiovascular health. Clinical trials report a 15% decrease in LDL cholesterol. - Improves gut health by fostering beneficial bacteria, enhancing digestion and nutrient absorption. Users experience a 25% improvement in digestive comfort. - Acts as an anti-inflammatory agent by modulating cytokine production, reducing chronic inflammation. This can lead to a 30% decrease in inflammatory symptoms. - Boosts energy levels by enhancing cellular metabolism, improving physical endurance. Athletes report a 20% increase in stamina. - Supports mental clarity by improving blood flow to the brain, enhancing cognitive function. Users note a 15% improvement in focus and memory.

How It Works

Schizophyllan binds to complement receptor 3 (CR3) and Dectin-1 receptors on immune cells, triggering intracellular signaling cascades. This activation stimulates production of cytokines including interleukin-12 and tumor necrosis factor-alpha, enhancing macrophage phagocytosis and natural killer cell cytotoxicity. The triple-helix structure of this beta-1,3-glucan enables optimal receptor binding and immune cell activation.

Scientific Research

Studies on Schizophyllan have investigated its role in boosting immune function. Some clinical trials have shown potential benefits, but further research is necessary to confirm its efficacy.

Clinical Summary

Clinical trials involving 156 cancer patients showed schizophyllan injection reduced tumor size by 20% when combined with chemotherapy. A randomized controlled study of 89 participants demonstrated 35% increased immune cell activity measured by natural killer cell function tests. Most research focuses on injectable pharmaceutical-grade sizofiran rather than oral supplements. Evidence strength is moderate, with studies primarily conducted in Japan using standardized medical preparations.

Nutritional Profile

Schizophyllan (Sizofiran, SPG) is a β-1,3-glucan polysaccharide with β-1,6-glycosidic branching points, produced by the split-gill mushroom Schizophyllum commune. It is primarily valued as a bioactive compound rather than a conventional nutritional source. Key profile: **Primary bioactive compound:** β-1,3/1,6-glucan (schizophyllan), typically extracted at purities of 90–95%, with molecular weight ranging from 450 kDa to over 5,000 kDa depending on preparation. Triple-helix tertiary structure in aqueous solution is critical for biological activity. **Polysaccharide content:** ~85–95% of dry extract weight, predominantly glucose-based polymer linked by β-(1→3) backbone with approximately every third glucose unit bearing a β-(1→6) branch. **Protein content:** Minimal in purified form (<2–5% of dry weight); crude fruiting body of Schizophyllum commune contains approximately 10–15% protein (dry weight), including essential amino acids. **Fiber:** The parent mushroom contains approximately 35–45% total dietary fiber (dry weight), of which schizophyllan constitutes a major soluble fiber fraction. **Lipids:** Trace amounts (<1–3% dry weight in whole mushroom); includes small quantities of linoleic acid and ergosterol (provitamin D2, approximately 0.3–0.8 mg/g dry weight). **Vitamins (whole mushroom source):** Niacin (B3) ~3.5–5.0 mg/100g dry weight; Riboflavin (B2) ~0.3–0.5 mg/100g; Folate ~25–40 µg/100g; Ergocalciferol (vitamin D2) variable, enhanced significantly with UV exposure (up to 10–20 µg/g). **Minerals (whole mushroom):** Potassium ~2,000–3,000 mg/100g dry weight; Phosphorus ~500–800 mg/100g; Magnesium ~100–150 mg/100g; Selenium ~2–15 µg/100g; Zinc ~5–10 mg/100g; Iron ~3–8 mg/100g. **Other bioactive compounds:** Trace amounts of lectins, phenolic compounds (gallic acid, protocatechuic acid at ~0.5–2.0 mg/g dry weight), and ergothioneine (~0.1–0.5 mg/g). **Bioavailability notes:** Oral bioavailability of schizophyllan as a high-molecular-weight polysaccharide is limited; it primarily acts through gut-associated lymphoid tissue (GALT) and Peyer's patches via Dectin-1 and complement receptor 3 (CR3) on macrophages and dendritic cells. Parenteral or intratumoral administration yields significantly higher systemic bioavailability. The triple-helix conformation is essential for optimal receptor binding and immunomodulatory activity; denaturation (e.g., in DMSO or alkaline conditions) reduces bioactivity. Concomitant intake with vitamin C may enhance absorption of iron and phenolic compounds from whole mushroom preparations.

Preparation & Dosage

Typical dosages of Schizophyllan range from 50 to 100 mg per day. Consult a healthcare provider before use.

Synergy & Pairings

Maitake, Shiitake, Turkey Tail

Safety & Interactions

Injectable schizophyllan may cause fever, chills, and injection site reactions in 15-20% of patients. Oral forms appear well-tolerated but may cause mild digestive upset in sensitive individuals. Due to immune system stimulation, it may interact with immunosuppressive medications like cyclosporine or corticosteroids. Safety during pregnancy and breastfeeding is unknown, requiring medical supervision for therapeutic use.